Viking Therapeutics Initiates Trial of VK2735 Maintenance Dosing Regimens in Obesity
MT newswire2026/10/06 11:5407:54 AM EDT, 10/06/2026 (MT Newswires) -- Viking Therapeutics (VKTX) said Tuesday it has begun a clinical trial to explore oral and additional subcutaneous VK2735 dosing regimens to maintain initial weight loss in patients with obesity. The maintenance dosing trial is the second of a two-part study initiated in 2025 and aims to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under various dosing regimens. Viking said that 195 adult participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks, after which they will transition to a range of VK2735 maintenance dosing options. The exploratory endpoints of the study will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33, it said. Shares of the company were up 1.4% in Tuesday's premarket activity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
